The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

Enhertu reduced the risk of disease progression ... in combination with chemotherapy for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no epidermal ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...

TOKYO, Japan & MUNICH, Germany I April 08, 2025 I DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of ...